Table 1.

Baseline characteristics of eligible adult and children with HBeAg-negative CHB

Baseline Characteristics	N, Value
Age (yrs)	n=1240
<18	90 (7.3%)
18-<30	130 (10.5%)
30-<50	619 (49.9%)
50-<60	254 (20.5%)
>=60	147 (11.9%)
Female	610 (49.2%)
Race	n=1236
White	154 (12.5%)
Black	185 (15.0%)
Asian	864 (69.9%)
Other/Mixed	33 (2.7%)
Phenotype *	n=1176
HBeAg- CHB	290 (24.7%)
Inactive carrier	366 (31.1%)
Indeterminant (IND)	520 (44.2%)
IND B	465 (89.4%)
IND C	55 (10.6%)
HBV Genotype	n=1096
A	204 (18.6%)
B	441 (40.2%)
C	301 (27.5%)
D	109 (9.9%)
Other (E, F, and multiple)	41 (3.8%)
Quantitative HBsAg (log10 IU/mL)	n=1110
Median(25th:75th)	3.2 (2.5: 3.8)
< 2	159 (14.3%)
2 – 3	299 (26.9%)
> 3	652 (58.7%)
Anti-HBe	n=1036
Positive	1001 (96.6%)
HBV DNA (log10 IU/mL)	n=1237
Median(25th:75th)	3.2 (2.4: 4.3)
<3	549 (44.4%)
3 - < 4	329 (26.6%)
4 - < 5	187 (15.1%)
≥ 5	172 (13.9%)
ALTxULN	n=1216
Median(25th:75th)	1.3 (0.9: 1.8)
≤1 ULN	416 (34.2%)
1< - ≤2 ULN	558 (45.9%)
> 2 ULN	242 (19.9%)
Platelets (x103/mm3)	n=1044
Median(25th:75th)	222.0 (182.5: 262.0)
APRI (AST-platelet-ratio index)	n=1035
Median(25th:75th)	0.3 (0.2: 0.4)
≤0.50	831 (80.3%)
>0.50–1.50	173 (16.7%)
>1.50	31 (3.0%)
BCP/PC Mutation (A1762T, G1764A, G1896A)	n=628
Wild type	178 (28.3%)
BCP only	152 (24.2%)
PC only	174 (27.7%)
BCP & PC	124 (19.7%)
Prior HBV treatment	n=131 (10.6%)
Median(25th:75th) year-to-entry	5.0 (1.3, 9.0)
Interferon	29 (17.9%)
Entecavir	23 (14.2%)
Telbivudine	6 (3.7%)
Lamivudine	48 (29.6%)
Adefovir	13 (8.0%)
Peg-interferon	19 (11.7%)
Tenofovir	10 (6.2%)
Unknown	14 (8.6%)

^*as per HBRN phenotype definitions (15). Inactive CHB defined by HBeAg-negative, normal ALT and HBV DNA ≤10,000 IU/mL, IND-B by HBeAg-negative, elevated ALT and HBV DNA ≤10,000 IU/mL and IND-C by HBeAg-negative, normal ALT and HBV DNA >10,000 IU/mL. Normal ALT was <30 U/L for males and <20 U/L for females.